Lack of GMP Training is Expensive: Lessons from Compounding Pharmacies

Since the passage of the Compounding Quality Act in late 2013, compounding pharmacies have had a rough experience trying to comply with tough GMP rules. Of the almost 60 compounding pharmacies that voluntarily registered with the FDA, almost 50 have gone through FDA’s audit for GMP compliance and all but one were found to be in significant GMP violations and … Read more

Updates to GCP and US Government Policies for Clinical Trial Patients

Much needed major updates to the GCP guidance and the Common Rule were proposed by the FDA and DHHS recently. These changes are being proposed to modernize the regulatory requirements to match the current practices for clinical trials. In one of the most comprehensive updates to the human subject protection rules that apply to clinical trials funded … Read more

Pharma Product Hopping and Product Evergreening in the Limelight Again

The “war” against high drug prices heats up even more this week when in a court filing Federal Trade Commission (FTC) strongly criticized practices used by the pharma companies to keep the drug prices high using questionable business and regulatory practices against generics. Pharma companies use two processes to increase the competitive advantage of their products over … Read more